Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2012 On August 13, 2012

Array BioPharma Inc. (Nasdaq:ARRY) will report financial results for the fourth quarter and full year of fiscal 2012 on Monday, August 13, 2012, and will hold a conference call on Tuesday, August 14, 2012 at 9:00 a.m. eastern time to discuss these results. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

Conference Call Information

Date:
  Tuesday, August 14, 2012

Time:
9:00 a.m. eastern time

Toll-Free:
800 561.2718

Toll:
617 614.3525

Pass Code:
62242246

Webcast & Conference Call Slides:

http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome
 

A replay of the call will be available as a webcast on www.arraybiopharma.com.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more information on Array, please go to www.arraybiopharma.com.

Copyright Business Wire 2010

If you liked this article you might like

This Isn't a Rally: Cramer's 'Mad Money' Recap (Monday 12/4/17)

This Isn't a Rally: Cramer's 'Mad Money' Recap (Monday 12/4/17)

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Mirati Skyrockets On Positive Data - Biotech Movers

Mirati Skyrockets On Positive Data - Biotech Movers

Array BioPharma Seems to Be in a New Uptrend

Array BioPharma Seems to Be in a New Uptrend